79691-11-5

Basic information

• Product Name: 6(R)-<2-<1,2,6,7,8,8a(R)-Hexahydro-2(S),6(R)-dimethyl-8(S)-<<2(S)-methylbutyryl>oxy>-1(S)-naphtyl>ethyl>-3,4,5,6-tetrahydro-4(R)-<(tert-butyldimethylsilyl)oxy>-2H-pyran-2-one
• Synonyms: 6(R)-<2-<1,2,6,7,8,8a(R)-Hexahydro-2(S),6(R)-dimethyl-8(S)-<<2(S)-methylbutyryl>oxy>-1(S)-naphtyl>ethyl>-3,4,5,6-tetrahydro-4(R)-<(tert-butyldimethylsilyl)oxy>-2H-pyran-2-one
• CAS NO: 79691-11-5
• Molecular Weight: 518.809
• Mol File: 79691-11-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 6(R)-<2-<1,2,6,7,8,8a(R)-Hexahydro-2(S),6(R)-dimethyl-8(S)-<<2(S)-methylbutyryl>oxy>-1(S)-naphtyl>ethyl>-3,4,5,6-tetrahydro-4(R)-<(tert-butyldimethylsilyl)oxy>-2H-pyran-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6(R)-<2-<1,2,6,7,8,8a(R)-Hexahydro-2(S),6(R)-dimethyl-8(S)-<<2(S)-methylbutyryl>oxy>-1(S)-naphtyl>ethyl>-3,4,5,6-tetrahydro-4(R)-<(tert-butyldimethylsilyl)oxy>-2H-pyran-2-one(79691-11-5)
• EPA Substance Registry System: 6(R)-<2-<1,2,6,7,8,8a(R)-Hexahydro-2(S),6(R)-dimethyl-8(S)-<<2(S)-methylbutyryl>oxy>-1(S)-naphtyl>ethyl>-3,4,5,6-tetrahydro-4(R)-<(tert-butyldimethylsilyl)oxy>-2H-pyran-2-one(79691-11-5)

Safety Data

• Hazardous Substances Data: 79691-11-5(Hazardous Substances Data)

Upstream product

• 27763-54-8 (S)-2-methylbutanoyl chloride 
• 79902-31-1 (4R,6R)-6-[2-((1S,2S,6R,8S,8aR)-8-hydroxy-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthyl)ethyl]-4-[(tert-butyldimethylsilyl)oxy]-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 288-32-4 1H-imidazole 
• 75330-75-5 lovastatin 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 85614-12-6 (S)-2-Methyl-butyric acid (1S,3S,7R,8R,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-3,7-dimethyl-6-oxo-1,2,3,4,6,7,8,8a-octahydro-naphthalen-1-yl ester 
• 96011-27-7 (S)-2-Methyl-butyric acid (1S,3R,4S,4aR,7S,8S,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-4-hydroxy-3,7-dimethyl-1,2,3,4,4a,7,8,8a-octahydro-naphthalen-1-yl ester 
• 153079-19-7 (S)-2-Methyl-butyric acid (1S,4S,6S,7R,8S,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-4-chloro-6-formyloxy-7-methyl-1,2,3,4,6,7,8,8a-octahydro-naphthalen-1-yl ester 
• 153079-21-1 (S)-2-Methyl-butyric acid (1S,4S,7R,8R,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-4-chloro-7-methyl-6-oxo-1,2,3,4,6,7,8,8a-octahydro-naphthalen-1-yl ester 
• 153079-22-2 (S)-2-Methyl-butyric acid (1S,3R,7R,8R,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-3,7-dimethyl-6-oxo-1,2,3,5,6,7,8,8a-octahydro-naphthalen-1-yl ester 
• 153079-20-0 (S)-2-Methyl-butyric acid (1S,4S,6S,7R,8S,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-4-chloro-6-hydroxy-7-methyl-1,2,3,4,6,7,8,8a-octahydro-naphthalen-1-yl ester 
• 153079-17-5 2-methyl-butyric acid 8-{2-[4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-7-methyl-6-oxo-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl ester 
• 153079-18-6 (S)-2-Methyl-butyric acid (1S,4S,6S,7R,8S,8aR)-4-chloro-6-formyloxy-8-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,4,6,7,8,8a-octahydro-naphthalen-1-yl ester 
• 153079-24-4 (S)-2-Methyl-butyric acid (1S,3R,7R,8R,8aR)-8-{2-[(2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-6-oxo-tetrahydro-pyran-2-yl]-ethyl}-3,7-dimethyl-6-trifluoromethanesulfonyloxy-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester 

Downstream Products

• 75330-75-5 lovastatin 
• 83268-63-7 4(R)-(tert-butyldimethylsiloxy)-6(R)-<2-<8(S)-(benzyloxy)-1,2,6,7,8,8a(S)-hexahydro-2(S),6(R)-dimethyl-1(S)-naphthyl>ethyl>-2-<(tetrahydropyran-2-yl)oxy>-3,4,5,6-tetrahydro-2H-pyran 
• 83268-64-8 4(R)-(tert-butyldimethylsiloxy)-6(R)-<2-<8(S)-(benzyloxy)-1,2,6,7,8,8a(S)-hexahydro-2(S),6(R)-dimethyl-1(S)-naphthyl>ethyl>-2-hydroxy-3,4,5,6-tetrahydro-2H-pyran 
• 83268-65-9 6(R)-<2-<8(S)-(benzyloxy)-1,2,6,7,8,8a(S)-hexahydro-2(S),6(R)-dimethyl-1(S)-naphthyl>ethyl>-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 103063-54-3 6(S)-<2-<8(S)-<<2(S)-methylbutanoyl>oxy>-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydro-1(S)-naphthyl>ethyl>-4-(R)-<(tert-butyldimethylsilyl)oxy>-3,4,5,6-tetrahydro-2H-pyran-2-one 
• 105227-51-8 lovastatin 
• 105227-52-9 (S)-2-Methyl-butyric acid (1S,3R,7S,8S,8aR)-3,7-dimethyl-8-(2-{(2S,4R)-4-[2-(4-nitro-phenyl)-acetoxy]-6-oxo-tetrahydro-pyran-2-yl}-ethyl)-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester 
• 102963-74-6 N-benzyl 7-<1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-<<2(S)-methylbutanoyl>oxy>-1(S)-naphthyl>-3(R)-<(tert-butyldimethylsilyl)oxy>-5(R)-hydroxyheptanoic acid amide 

Relevant articles and documents

Stereocontrolled functionalization of the diene system of compactin

A facile regio- and stereo selective γ-functionlization of the 1,3-diene system of compactin via the key dienone 3 is described.

Remote Diastereoselection in the Asymmetric Total Synthesis of Mevinolin

The asymmetric total synthesis of mevinolin (1a) is described.The key diastereoselective processes used to parlay the lone stereogenic center of asymmetrically produced (S)-pulegone (2a) to mevinolin include orthoester-Claisen rearrangement of 2d to 3a, stereoselective iodolactonization of 3e to 4, Eschenmoser-Claisen rearrangement of 6 to 7a, stereoselective intramolecular ene reaction of 7b to 8, and a highly diastereoselective cyclocondesation of aldehyde 10 with Danishefsky's diene.The cyclocondensation reaction was found to be quite sensitive to the reactionconditions in which the use of TiCl4 produced a 90:10 mixture of 11/12 while MgBr2 gave a 22:78 mixture

Reductive Transformation and Cyclopropanation of Mevinolin (α-Methylcompactin). Generation of Chirality in the 1,4-Hydrostannation of a Cyclic Diene

Conversion of mevinolin by direct reductive procedures as well as by indirect chemical transformations has permitted the preparation of the various di- and tetrahydro derivatives.Cyclopropanation of mevinolin and its derivatives has furnished mono- and di